meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA) 1
mEC - 1st line (L1) 1
mEC - 2nd line (L2) 3
gastric or gastroesophageal junction cancer (GC)

immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus SoC

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -